A study of AL101 in patients with ACC (ACCURACY) is a phase II multicentre trial analysing the effect of Notch inhibitor AL101 in R/M ACC patients harbouring Notch1-, Notch2-, Notch3- or Notch4-activating mutations. Here, NOTCH3 is linked to adrenal cortex carcinoma.